Although we were not able to pinpoint the exact origin of plasma NGAL levels (i.e., discriminating between different isoforms of the protein), the fact that NGAL may reflect both chronic low-grade systemic inflammation and renal tubular injury may render it a potentially useful clinical biomarker for new-onset CKD. This evidence concerns the gene LCN2 and chronic kidney disease.